TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10978257

Group type: EXPERIMENTAL
Intervention: Simvastatin therapy (20 mg per day for 4 months)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 64
Study: 8986917

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg once a day
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once a day
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 1335643

Group type: EXPERIMENTAL
Intervention: Vaccine-induced antibodies after booster dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine-induced antibodies after primary doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine-induced antibodies considering minimal individual titre
Number of subjects: 0
Study: 3992397

Group type: EXPERIMENTAL
Intervention: Premature formula for a further 8 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 10
Study: 30608444

Group type: EXPERIMENTAL
Intervention: OSTAP block with 40 mL of 0.375% bupivacaine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham group with 40 mL of 0.9% saline
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: OSTAP block
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 66
Study: 28371204

Group type: EXPERIMENTAL
Intervention: Tripeptide/hexapeptide system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bland dimethicone-based ointment and petrolatum-based cream
Number of subjects: 15
Study: 26643786

Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate (MAL) and daylight
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo and daylight
Number of subjects: 60
Study: 23934539

Group type: EXPERIMENTAL
Intervention: SPTB (spontaneous preterm birth)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: IPTB (medically indicated preterm birth)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Composite neonatal morbidity
Number of subjects: 606

Group type: COMPARATOR
Intervention: NICU admission
Number of subjects: 606

Group type: COMPARATOR
Intervention: Perinatal death
Number of subjects: 606
Study: 21730016

Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg, 8 mg, 12 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 12
Study: 20560291

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (5 mcg every 2-3 hours while awake)
Number of subjects: 22
Study: 17200170

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training + weight loss (AEX + WL)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Aerobic exercise training (AEX)
Number of subjects: 46
Study: 15850603

Group type: EXPERIMENTAL
Intervention: Estrogen (conjugated equine estrogen [CEE] 0.625 mg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 11975107

Group type: EXPERIMENTAL
Intervention: Micropuncture technique
Number of subjects: 48

Group type: COMPARATOR
Intervention: Large-bore needle approach
Number of subjects: 48
Study: 10096309

Group type: EXPERIMENTAL
Intervention: Alcohol (blood alcohol concentration mean = .08 mg%)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Expectation of alcohol disinhibition
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: COMPARATOR
Intervention: Water
Number of subjects: 161
Study: 7635769

Group type: EXPERIMENTAL
Intervention: Treatment duration < 55 days
Number of subjects: 209

Group type: COMPARATOR
Intervention: Treatment duration >= 55 days
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Stage IB/IIA treatment duration < 55 days
Number of subjects: 209

Group type: COMPARATOR
Intervention: Stage IB/IIA treatment duration >= 55 days
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Stage III treatment duration < 55 days
Number of subjects: 209

Group type: COMPARATOR
Intervention: Stage III treatment duration >= 55 days
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Stage IIB treatment duration < 55 days
Number of subjects: 209

Group type: COMPARATOR
Intervention: Stage IIB treatment duration >= 55 days
Number of subjects: 209
Study: 2144391

Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination (20 micrograms)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Intradermal vaccination (2 micrograms)
Number of subjects: 69
Study: 625669

Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine prophylaxis
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no phenoxybenzamine)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine treatment after urinary retention
Number of subjects: 43
Study: 30973482

Group type: EXPERIMENTAL
Intervention: High-intensity agility exergaming (EXE)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Stationary cycling (CYC)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Waitlisted controls (CON)
Number of subjects: 55
Study: 28019652

Group type: EXPERIMENTAL
Intervention: Reduction in WHO risk drinking levels during treatment
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Greater reduction in WHO risk drinking levels
Number of subjects: 1383
Study: 25678325

Group type: EXPERIMENTAL
Intervention: INCENT (individually targeted Internet‐based intervention with monetary incentives)
Number of subjects: 1790

Group type: COMPARATOR
Intervention: LMW (Livin' My Weigh, less‐intensive intervention)
Number of subjects: 1790
Study: 25212749

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.5mg/day)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sertraline (200mg/day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.5mg/day) with DRD4 >7 repeats
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sertraline (200mg/day) with DRD4 <7 repeats
Number of subjects: 77
Study: 23094559

Group type: EXPERIMENTAL
Intervention: Twin-block
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Forsus (FRD)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 19575791

Group type: EXPERIMENTAL
Intervention: Brief lifestyle counselling delivered by an Alcohol Health Worker (AHW)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Short screening instruments (M-SASQ, FAST, SIPS-PAT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Screening and brief interventions
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Performance using a gold-standard screening test (AUDIT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quantity and frequency of alcohol consumed
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alcohol-related problems
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Motivation to change
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Health related quality of life
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Service utilisation
Number of subjects: 9
Study: 17265490

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate 1,500 mg once daily (n = 106)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Acetaminophen 3 gm/day (n = 108)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo (n = 104)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 15354322

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 6 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 0
Study: 11823887

Group type: EXPERIMENTAL
Intervention: 192 mg naltrexone base
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 384 mg naltrexone base
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9821032

Group type: EXPERIMENTAL
Intervention: Standardised B-mode ultrasonic images of carotid plaques
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Video and magneto-optical disk (MOD) recording media
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Standardised images of symptomatic plaques
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Presence of plaque echolucency
Number of subjects: 119
Study: 8129157

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2488911

Group type: EXPERIMENTAL
Intervention: S-Amp (sulbactam plus ampicillin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amp (ampicillin)
Number of subjects: 100
Study: 7359644

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 32
Study: 30845335

Group type: EXPERIMENTAL
Intervention: Typhoid conjugate vaccine
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 20000
Study: 27676275

Group type: EXPERIMENTAL
Intervention: Soccer training (2 seasons)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no soccer training)
Number of subjects: 40
Study: 26194476

Group type: EXPERIMENTAL
Intervention: Family planning education program (6 months duration)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Routine health care services (control group)
Number of subjects: 811
Study: 23808885

Group type: EXPERIMENTAL
Intervention: Telehealth intervention with home-based telehealth equipment and ongoing remote monitoring by a nurse.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information-only control group.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telehealth intervention.
Number of subjects: 0
Study: 20528880

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1010
Study: 19474181

Group type: EXPERIMENTAL
Intervention: attend smoking group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: avoid smoking group
Number of subjects: 72

Group type: COMPARATOR
Intervention: control group
Number of subjects: 72
Study: 17214993

Group type: EXPERIMENTAL
Intervention: AGI‐1067 280 mg qd for 12 months after PCI
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: AGI‐1067
Number of subjects: 232
Study: 15470797

Group type: EXPERIMENTAL
Intervention: 0.4 mg naloxone administered intravenously
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 9
Study: 11350523

Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine+1.2% PVP
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine+5% PVP
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine+10% PVP
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.03% chlorhexidine
Number of subjects: 6
Study: 9077376

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 543

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels
Number of subjects: 543
Study: 8339809

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1 mg/day
Number of subjects: 154

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 2 mg/day
Number of subjects: 154
Study: 3085789

Group type: EXPERIMENTAL
Intervention: Sodium etidronate 20 mg/kg/day for two and four weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium etidronate 20 mg/kg/day for four weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium etidronate 20 mg/kg/day for two weeks
Number of subjects: 11
Study: 11578893

Group type: EXPERIMENTAL
Intervention: Air-O(2) mixture with FGF 0.5 L/min (4/1 ratio)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Air-O(2) mixtures with FGF < or = 2 L/min
Number of subjects: 160
Study: 31164972

Group type: EXPERIMENTAL
Intervention: AAF with synbiotics (prebiotic fructo‐oligosaccharides and probiotic Bifidobacterium breve M‐16V)
Number of subjects: 71

Group type: COMPARATOR
Intervention: AAF without synbiotics (control)
Number of subjects: 71
Study: 28921338

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (20,000 IU per week)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study: 26516803

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided single-injection infraclavicular block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrasound-guided double-injection axillary block
Number of subjects: 0
Study: 24619917

Group type: EXPERIMENTAL
Intervention: Pradigastat co-administered with digoxin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pradigastat co-administered with warfarin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 40
Study: 22515886

Group type: EXPERIMENTAL
Intervention: 1.9 mL of lidocaine (76.4 mg) with epinephrine plus 0.5 mol/L mannitol
Number of subjects: 106

Group type: COMPARATOR
Intervention: Lidocaine with epinephrine (without mannitol)
Number of subjects: 106
Study: 20233195

Group type: EXPERIMENTAL
Intervention: Infusional pantoprazole at 192 mg day(-1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Infusional pantoprazole at 160 mg day(-1) (40 mg every 6 h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 18068064

Group type: EXPERIMENTAL
Intervention: Fenoldopam infusion (0.1 microg/kg/min)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 15654790

Group type: EXPERIMENTAL
Intervention: Alosetron 1.0 mg twice daily
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Alosetron (all doses)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Alosetron (0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg)
Number of subjects: 662
Study: 12190178

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 86
Study: 11052040

Group type: EXPERIMENTAL
Intervention: Evidence-based pain management content, education of care providers and patients, and system changes at the point of care
Number of subjects: 118
Study: 7634779

Group type: EXPERIMENTAL
Intervention: 8% fragrance mix with 1% sorbitan sesquioleate (SSO)
Number of subjects: 709

Group type: COMPARATOR
Intervention: 8% fragrance mix without SSO
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: 20% sorbitan sesquioleate (SSO)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: 8% fragrance mix with 1% SSO
Number of subjects: 709
Study: 2106806

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 474334

Group type: EXPERIMENTAL
Intervention: Peppermint oil
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Smelling salts
Number of subjects: 14
Study: 30395842

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (300,000 IU intramuscular injection)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 28532200

Group type: EXPERIMENTAL
Intervention: Spinal analgesia with clonidine
Number of subjects: 135

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 135
Study: 25391382

Group type: EXPERIMENTAL
Intervention: Antidementia drugs (memantine, donepezil, rivastigmine, galantamine)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Antidementia drugs
Number of subjects: 243
Study: 23751938

Group type: EXPERIMENTAL
Intervention: Ambrisentan + spironolactone
Number of subjects: 199

Group type: COMPARATOR
Intervention: Ambrisentan
Number of subjects: 199
Study: 22070741

Group type: EXPERIMENTAL
Intervention: Ice-lolly
Number of subjects: 92

Group type: COMPARATOR
Intervention: No ice-lolly (Control)
Number of subjects: 92
Study: 19176739

Group type: EXPERIMENTAL
Intervention: Moderate-calcium, low-phytate diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moderate-calcium, high-phytate diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-calcium, low-phytate diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-calcium, high-phytate diet
Number of subjects: 10
Study: 17403911

Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status (SES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptions that parents support fighting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive behavior in girls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Level of aggression in boys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affiliating with aggressive peers (boys)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affiliating with aggressive peers (girls)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptions of parents' attitudes toward fighting
Number of subjects: 0
Study: 15560326

Group type: EXPERIMENTAL
Intervention: Feedback Condition (pedometers)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No-feedback Condition (sealed 'disguised' pedometers)
Number of subjects: 26
Study: 11330505

Group type: EXPERIMENTAL
Intervention: Intact insulin
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: C-peptide
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: ApoB
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Cigarette years
Number of subjects: 391
Study: 9208964

Group type: EXPERIMENTAL
Intervention: Initial Arterial Revascularization (IAR)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Initial Portal Revascularization (IPR)
Number of subjects: 29
Study: 7963303

Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release
Number of subjects: 104

Group type: COMPARATOR
Intervention: Endoscopic carpal tunnel release
Number of subjects: 104
Study: 3595143

Group type: EXPERIMENTAL
Intervention: Triphasil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ortho 777
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ortho 10/11
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not on OCs for at least 3 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triphasil (in women not on OCs at the start)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ortho 777 and Ortho 10/11 (combined)
Number of subjects: 0
Study: 31919502

Group type: EXPERIMENTAL
Intervention: Human serum metabolite 2-methoxyacetaminophen sulfate
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Human serum metabolite 1-docosahexaenoylglycerophosphocholine
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Metabolic pathway glycine, serine, and threonine metabolism
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Metabolic pathway Aminoacyl-tRNA biosynthesis
Number of subjects: 486
Study: 31710013

Group type: EXPERIMENTAL
Intervention: Probiotic milk
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluoride mouthwash
Number of subjects: 30
Study: 28724582

Group type: EXPERIMENTAL
Intervention: Seizure pattern of eye involvement without motor automatisms
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Seizure semiology features (pause/stare, motor automatisms, eye involvement)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Seizure clusters (presence/absence of eye involvement and motor automatisms)
Number of subjects: 416
Study: 25416584

Group type: EXPERIMENTAL
Intervention: Scapulothoracic joint control training exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard rehabilitation interventions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of standard rehabilitation interventions and scapulothoracic joint control training exercises
Number of subjects: 40
Study: 23724494

Group type: EXPERIMENTAL
Intervention: High magnification sperm isolation for ICSI
Number of subjects: 2

Group type: COMPARATOR
Intervention: Normal magnification sperm isolation for ICSI
Number of subjects: 2
Study: 21387983

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling plus systemic antibiotics
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling
Number of subjects: 29

Group type: COMPARATOR
Intervention: Quadrant scaling
Number of subjects: 29
Study: 19318950

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16360199

Group type: EXPERIMENTAL
Intervention: Low-dose Z-100 (0.2 microg)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: High-dose Z-100 (40 microg)
Number of subjects: 221
Study: 15279498

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sucrose-containing beverage
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo gum (no nicotine)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Aspartame-containing beverage
Number of subjects: 14
Study: 10378565

Group type: EXPERIMENTAL
Intervention: Kinetic therapy (KT) combined with mechanical percussion (P) using a KT system (Triadyne Kinetic Therapy System; KCI; San Antonio, TX)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Manual repositioning and manual percussion every 2 h (Control group)
Number of subjects: 24
Study: 8777824

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (8.5‐10.5 mmol/l)
Number of subjects: 11
Study: 1380475

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion during ERCP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo during ERCP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6833466

Group type: EXPERIMENTAL
Intervention: Dermorphin (5.5 micrograms/kg . min for 30 min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dermorphin during naloxone infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: D-placebo (0.9% saline)
Number of subjects: 11